China Biopharmaceutical (01177): Latest research results of TQ-A3334 "TLR7 agonist" and Bepirovirsen "ASO" to be presented at 2026 AASLD

Zhito Finance APP News: China Biopharmaceutical (01177) has announced that a clinical study result of TQ-A3334 (TLR7 agonist), a National Class 1 innovative drug independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) for the 2026 American Association for the Study of Liver Diseases (AASLD) Annual Meeting and will be presented in an oral presentation; Bepirovirsen (ASO), a strategic collaboration product between Chia Tai Tianqing and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).